2-[[2-formamido-4-(methylthio)-1-oxobutyl]amino]propanoic acid profile

ID Source	ID
PubMed CID	4363
CHEMBL ID	2130597
CHEBI ID	91785
SCHEMBL ID	4287202

Synonym
n-formyl-met-ala
smr001306773
MLS002207228
KBIO1_000925
DIVK1C_000925
SPECTRUM_001190
n-formylmethionylalanine
NCGC00178212-01
IDI1_000925
SPECTRUM5_001229
n-formyl-met-ala, >=95% (hplc)
BSPBIO_003197
KBIOSS_001670
KBIO2_004238 ,
KBIO2_001670
KBIO3_002697
KBIO2_006806
KBIOGR_000549
SPECTRUM3_001519
SPBIO_001020
SPECTRUM2_001060
SPECTRUM4_000055
NINDS_000925
HMS502O07
CCG-40124
CHEMBL2130597
SCHEMBL4287202
DTXSID10274432
CHEBI:91785
2-[[2-formamido-4-(methylthio)-1-oxobutyl]amino]propanoic acid
Q27163587

Class	Description
peptide	Amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
USP1 protein, partial	Homo sapiens (human)	Potency	28.1838	0.0316	37.5844	354.8130	AID743255
TDP1 protein	Homo sapiens (human)	Potency	1.7803	0.0008	11.3822	44.6684	AID686978; AID686979
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay ID	Title	Year	Journal	Article
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (14.29)	29.6817
2010's	5 (71.43)	24.3611
2020's	1 (14.29)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (14.29%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (85.71%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Description	Relationhip Strength	Classes	Roles
enkephalin, leucine	[no description available]	low	peptide
n-formylmethionylphenylalanine	[no description available]	low	peptide
substance p	[no description available]	low	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent
enalkiren	[no description available]	low	peptide
kynostatin 272	[no description available]	low	peptide
terlakiren	[no description available]	low	peptide
kni 102	[no description available]	low	peptide
pidotimod	[no description available]	low	peptide
cefpimizole	[no description available]	low	peptide
aspoxicillin	[no description available]	low	peptide
pro-diazepam	[no description available]	low	peptide
moexipril	[no description available]	low	peptide
mci 9038	[no description available]	low	peptide
leucylleucine	[no description available]	low	peptide
diprotin a	[no description available]	low	peptide
fk 888	[no description available]	low	peptide
calpain inhibitor 2	[no description available]	low	peptide
formylmethionyl-leucyl-phenylalanine methyl ester	[no description available]	low	peptide
t-kinin	[no description available]	low	peptide
3-(n-maleimidopropionyl)biocytin	[no description available]	low	peptide
cefbuperazone	[no description available]	low	cephalosporin; peptide
endothelin (16-21)	[no description available]	low	peptide
n-valyltryptophan	[no description available]	low	peptide
neurotensin (1-8)	[no description available]	low	peptide zwitterion; peptide	human metabolite
alanylaspartic acid	[no description available]	low	peptide
fibrin	[no description available]	low	peptide
n-carbobenzoxyglycylproline	[no description available]	low	peptide
s-(4-azidophenacyl)glutathione	[no description available]	low	peptide
bq 485	[no description available]	low	peptide
phenylalanine arginine beta-naphthylamide	[no description available]	low	peptide
teprotide	[no description available]	low	peptide
ro 09-1437	[no description available]	low	peptide
N-[2-[[2-(cyclopentylamino)-2-oxo-1-pyridin-4-ylethyl]-(thiophen-2-ylmethyl)amino]-2-oxoethyl]-2-furancarboxamide	[no description available]	low	peptide
N-[2-[1,3-benzodioxol-5-yl-[2-(cyclopentylamino)-2-oxo-1-pyridin-4-ylethyl]amino]-2-oxoethyl]-2-furancarboxamide	[no description available]	low	peptide
N-[1-[(1-amino-4-methyl-1-oxopentan-2-yl)amino]-3-methyl-1-oxopentan-2-yl]carbamic acid tert-butyl ester	[no description available]	low	peptide
N-tert-butyl-N-[2-(tert-butylamino)-2-oxoethyl]-3-(3,4-dihydro-2H-quinolin-1-yl)propanamide	[no description available]	low	peptide
N-[2-[1,3-benzodioxol-5-yl-[2-(tert-butylamino)-2-oxo-1-pyridin-4-ylethyl]amino]-2-oxoethyl]-2-furancarboxamide	[no description available]	low	peptide
N-[2-(4-chloro-N-[2-(cyclohexylamino)-2-oxoethyl]anilino)-2-oxoethyl]-2-furancarboxamide	[no description available]	low	peptide
2-[(2-acetamido-1-oxoethyl)amino]-3-phenylpropanoic acid ethyl ester	[no description available]	low	peptide
deltorphin	[no description available]	low	peptide
angiotensin iii, 5-ile-	[no description available]	low	peptide
N-[2-[butyl-[2-(cyclopentylamino)-2-oxo-1-pyridin-4-ylethyl]amino]-2-oxoethyl]-2-thiophenecarboxamide	[no description available]	low	peptide
2-[[2-(cyclohexylamino)-2-oxo-1-thiophen-2-ylethyl]-[1-oxo-2-[[oxo(thiophen-2-yl)methyl]amino]ethyl]amino]acetic acid ethyl ester	[no description available]	low	peptide
N-[2-[[2-(cyclohexylamino)-2-oxo-1-thiophen-2-ylethyl]-(2-methoxyethyl)amino]-2-oxoethyl]-2-furancarboxamide	[no description available]	low	peptide
4-hydroxy-1-[1-oxo-2-(phenylmethoxycarbonylamino)propyl]-2-pyrrolidinecarboxylic acid	[no description available]	low	peptide
4-hydroxy-1-[1-oxo-2-[[1-oxo-2-(phenylmethoxycarbonylamino)ethyl]amino]propyl]-2-pyrrolidinecarboxylic acid (phenylmethyl) ester	[no description available]	low	peptide
2-[(2-acetamido-1-oxoethyl)amino]-N-(4-methoxyphenyl)-2-(4-methylphenyl)acetamide	[no description available]	low	peptide
mureidomycin a	[no description available]	low	peptide
kallidin	[no description available]	low	peptide
delapril	[no description available]	low	peptide
(2R)-2-[[(2R,3R,4R)-2-amino-4-hydroxy-4-(5-hydroxy-2-pyridinyl)-3-methyl-1-oxobutyl]amino]-2-[(2S,3R,4S,5S)-5-(2,4-dioxo-1-pyrimidinyl)-3,4-dihydroxy-2-oxolanyl]acetic acid	[no description available]	low	peptide
enkephalin, ala(2)-mephe(4)-gly(5)-	[no description available]	low	peptide
l 685458	[no description available]	low	carbamate ester; monocarboxylic acid amide; peptide; secondary alcohol	EC 3.4.23.46 (memapsin 2) inhibitor; peptidomimetic
alvimopan anhydrous	[no description available]	low	peptide
leucokinin i	[no description available]	low	peptide
s-(1,2-dichlorovinyl)glutathione	[no description available]	low	peptide
cyanoginosin-la	[no description available]	low	peptide
(3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-1-oxopropyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid	[no description available]	low	peptide
lenampicillin	[no description available]	low	peptide
glycyl-alanyl-leucine	[no description available]	low	peptide
leucyl-leucine-methyl ester	[no description available]	low	peptide
valyl-valyl-valine	[no description available]	low	peptide
(3S)-N-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide	[no description available]	low	peptide
ly 450139	[no description available]	low	peptide
flag peptide	[no description available]	low	peptide
carbobenzoxy-leucyl-leucyl-norvalinal	[no description available]	low	peptide
l 692585	[no description available]	low	peptide
deltorphin ii, ala(2)-	[no description available]	low	peptide
deltorphin i, ala(2)-	[no description available]	low	peptide
eledoisin	[no description available]	low	peptide
icg 001	[no description available]	low	peptide
darinaparsin	[no description available]	low	peptide
ubenimex	[no description available]	low	peptide
rhizocticin a	[no description available]	low	peptide
(2S)-2-[[[1-[(2S)-3-methyl-2-[(4-methylphenyl)sulfonylamino]-1-oxobutyl]-4-piperidinyl]-oxomethyl]amino]-2-phenylacetic acid	[no description available]	low	peptide
(2R)-2-[[(3S)-3-acetamido-3-carboxy-1-oxopropyl]amino]pentanedioic acid	[no description available]	low	peptide
alamandine	[no description available]	low	peptide
(3S)-3-[[[(2S)-1-[(2S)-2-[[(4-amino-3-chlorophenyl)-oxomethyl]amino]-3,3-dimethyl-1-oxobutyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-cyanopropanoic acid	[no description available]	low	peptide
tuftsin	[no description available]	low	peptide
microcystin	[no description available]	low	peptide
thiocoraline	[no description available]	low	peptide
glutamyl-valyl-glycine	[no description available]	low	peptide
prolyl-glycyl-proline	[no description available]	low	peptide

Condition	Relationship Strength	Studies
Anemia, Fanconi	low	1
Benign Neoplasms	low	1
Cancer	low	1
Fanconi Anemia	low	1
Fanconi Hypoplastic Anemia	low	1
Fanconi Pancytopenia	low	1
Fanconi Panmyelopathy	low	1
Fanconi's Anemia	low	1
Inflammation	low	1
Innate Inflammatory Response	low	1
Malignancy	low	1
Malignant Neoplasms	low	1
Neoplasia	low	1
Neoplasm	low	1
Neoplasms	low	1
Neoplasms, Benign	low	1
Tumors	low	1

2-[[2-formamido-4-(methylthio)-1-oxobutyl]amino]propanoic acid

Cross-References

Synonyms (31)

Drug Classes (1)

Protein Targets (2)

Potency Measurements

Bioassays (15)

Research

Studies (7)

Study Types

2-[[2-formamido-4-(methylthio)-1-oxobutyl]amino]propanoic acid

Cross-References

Synonyms (31)

Drug Classes (1)

Protein Targets (2)

Potency Measurements

Bioassays (15)

Research

Studies (7)

Study Types

Related Drugs (83)

Related Conditions (17)